Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) saw a large drop in short interest in July. As of July 15th, there was short interest totaling 200 shares, a drop of 97.2% from the June 30th total of 7,045 shares. Based on an average daily volume of 3,664 shares, the short-interest ratio is currently 0.1 days.
Clinuvel Pharmaceuticals Stock Performance
The stock’s fifty day moving average is $6.96 and its 200 day moving average is $7.22. Clinuvel Pharmaceuticals has a 12-month low of $5.98 and a 12-month high of $9.00.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
See Also
- Five stocks we like better than Clinuvel Pharmaceuticals
- 2 Stocks Built to Thrive If Inflation Refuses to Fade
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
